Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 14/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | FPR1 | P21462 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3977360 | 0.99 | FFAR4 (0.37) | FFAR4PDK2HTR7KCNN4OPRM1 | |
| SCHEMBL3978122 | 0.79 | FFAR4 (0.39) | FFAR4 | |
| Hydrochloric Acid SCHEMBL3970114 | 0.78 | FFAR4 (0.39) | FFAR4 | |
| SCHEMBL13654237 | 0.65 | CYP1A2 (0.47) | FFAR4 | |
| SCHEMBL7238180 | 0.61 | PDK2 (0.48) | PDK2 | |
| SCHEMBL3818272 | 0.61 | PDK2 (0.48) | PDK2KCNN4P2RY1 | |
| SCHEMBL21122616 | 0.61 | MAPK14 (0.35) | FFAR4PDK2HTR7 | |
| SCHEMBL1041243 | 0.60 | PDK2 (0.49) | FFAR4PDK2HTR7KCNN4 | |
| SCHEMBL671924 | 0.60 | AOC3 (0.38) | — | |
| Hydrochloric Acid SCHEMBL3970783 | 0.59 | FFAR4 (0.38) | FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HRH3, HRH2, HRH4 | FFAR4 412/4885PDK2 2012/4885HTR7 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.